Phase I Study of Lonsurf in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting
18 years - 100 years
All
1 Location

Brief description of study

The purpose of this study is to see whether a chemotherapy drug called Lonsurf (TAS-102) could be given safely with other chemotherapy agents (gemcitabine and nab-paclitaxel), and to assess the good and bad effects this treatment might have. Gemcitabine and nab-paclitaxel are approved by the Food and Drug Administration (FDA) for the treatment of pancreatic cancer.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: pancreatic cancer,Pancreatic Ductal Adenocarcinoma
  • Age: 18 years - 100 years
  • Gender: All

Inclusion Criteria

Untreated locally advanced PDAC
Histologically or cytologically confirmed PDAC
Adequate organ function
Women of childbearing potential definition (WOCBP) must have a negative serum or urine pregnancy test performed within 14 days prior to initiation of study treatment.

Updated on 04 Aug 2024. Study ID: 1811447298 (IUSCC-0664)

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Zip Code
Please provide your 5-digit zip code
0 0 /250
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team